ARWR - Arrowhead Pharmaceuticals, Inc.
| Previous Close | 12.2100 |
| Open | 11.7300 |
| Bid | 11.9400 x 200 |
| Ask | 12.0300 x 100 |
| Day's Range | 11.5501 - 12.2950 |
| 52 Week Range | 3.0100 - 22.3900 |
| Volume | 393,942 |
| Avg. Volume | 2,592,087 |
| Market Cap | 1.063B |
| Beta (3Y Monthly) | 3.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6810 |
| Earnings Date | Dec 10, 2018 - Dec 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.30 |
- Business Wire•11 days ago
Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018
- Mean HBsAg reduction of -1.9 Log10 with a range of -1.3 Log10 to -3.8 Log10
- Business Wire•11 days ago
Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018
PASADENA, Calif.-- -- Three monthly doses of 300 mg ARO-AAT led to reductions in serum alpha-1 antitrypsin to below the level of quantitation in 100% of subjects Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible Single and multiple doses of ARO-AAT appear to be well-tolerated at all doses tested Arrowhead Pharmaceuticals Inc. today ...
- Motley Fool•13 days ago
Here's Why Arrowhead Pharmaceuticals Dropped 33.6% in October
The company de-risked the development of its potential blockbuster hepatitis B drug for a cool $250 million. Investors thought the price was too low.
- Business Wire•19 days ago
Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:
- Business Wire•20 days ago
Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen
Arrowhead Pharmaceuticals Inc. today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the stock purchase agreement between Arrowhead and Johnson & Johnson Innovation – JJDC, Inc., have closed, following termination of the waiting period under ...
- Motley Fool•28 days ago
Why Investors Are Paying a Premium for These 3 Biotech Stocks
Here's how shares of these drugmakers surged to nosebleed valuations.
- GlobeNewswire•28 days ago
Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- TheStreet.com•last month
The Rally in Arrowhead Pharmaceuticals Has Been Impressive - Now What?
In this daily bar chart of ARWR, below, we can see some strong price performance from December with prices rallying from $4 to touch $22 - impressive. The daily On-Balance-Volume (OBV) line shows an interesting rise from November to September. In this weekly bar chart of ARWR, below, we can see a parabolic rally from just $2 back in 2017 to $22 - one heck of a return.
- Business Wire•last month
Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform. In addition to senior members of the Arrowhead team, the R&D Day includes, Ira J. Goldberg, M.D., Bronfman Professor of Medicine, Chief of the Division of Endocrinology, Diabetes, and Metabolism, New York University Langone School of Medicine. A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
- CNBC•last month
Johnson & Johnson tops third-quarter earnings, revenue estimates
Pharmaceuticals have been fueling J&J's growth while its consumer and medical device businesses have lagged.
- Business Wire•last month
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
— Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics
Motley Fool•last monthThis 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging
Find out which earnings report you really need to pay attention to next week.
- Motley Fool•last month
Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September
Investors are excited about data for its hepatitis B drug.
- Business Wire•last month
Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
Arrowhead Pharmaceuticals Inc. will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease being held on November 9-13, 2018, in San Francisco.
- ACCESSWIRE•last month
Major Biotech Announcements Moving the Market
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
Market Realist•last monthWhy Arbutus Biopharma Stock Plunged 24.4% Today
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.
- InvestorPlace•last month
ARWR Stock Sinks After Signing a Big Collaboration Deal
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
- Market Realist•last month
JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug
On October 4, Johnson & Johnson (JNJ) announced an exclusive worldwide license agreement with Arrowhead Pharmaceuticals (ARWR) to develop and commercialize the latter’s Phase 1/2 drug candidate for the treatment of chronic Hepatitis B viral infection.
Market Realist•last monthHow Is Arrowhead Pharmaceuticals Stock Positioned?
When the market opened in 2018, Arrowhead Pharmaceuticals stock was selling at $3.69. Cantor Fitzgerald has raised its target price for Arrowhead Pharmaceuticals to $24 from $18. In July, Chardan Capital raised its price target to $24.50 from $17.50.
- Motley Fool•last month
Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?
A market beatdown following some good news has investors scratching their heads.
- Zacks•2 months ago
J&J Inks Deal With Arrowhead for Promising Liver Candidate
Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.
Zacks•2 months agoPharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones ...
- Reuters•2 months ago
J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide licence for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology. J&J's investment comes a month after Arrowhead released data from an early trial testing ARO-HBV, dubbed "revolutionary" by analysts who also said the company was positioned to develop a functional cure for Hepatitis B. It also follows the first U.S. approval for an RNAi drug - Alnylam Pharmaceuticals' (ALNY.O) Onpattro - in August that affirmed the gene-silencing class of drugs as a new frontier in the field of medicine.
- The Wall Street Journal•2 months ago
[$$] Honey, I Shrunk the Biotech Deal
Arrowhead Pharmaceuticals touted a deal with Johnson & Johnson with a price tag more than the double the company’s market value, but the actual figure may be far smaller.
